BPC157 exerts a significant protective effect on various tissues and organs, such as the esophagus, stomach, duodenum [2], colorectal mucosa [2], liver, pancreas [3], muscle [4], cornea [5], heart [6] and nerves [7]
Run both for 2 to 4 weeks, then cycle off together
The drugs would still not be FDA-approved, and the FDA would still not vouch for their safety or effectiveness. Koehl Robinson, founder and CEO of CeliaRX, a telehealth company that sells injectable and topical peptides compounded by a 503A pharmacy partner (not the ones on the FDAs potential unbanned list), says that if the peptides are reclassified, it would likely open up new possibilities for her customers, as well as lead to more clarity and less confusion
We're going to get to the bottom of this debate below